This biweekly Women’s Health video recap highlights regulatory momentum in advanced breast cancer, positive late-stage oncology data, expanding endometriosis and fertility pipelines, femtech AI innovation, policy advocacy, and platform-driven care consolidation.
🎯 Watch Our Video Summary Capturing Top Women’s Health News from the Last Two Weeks
Dive deeper
📚 View the full Women’s health archive on our research hub page.
Top Stories Covered in This Video
Chapters
0:00 Introduction
0:08 Roche NDA accepted for giredestrant combo in ESR1-mutated advanced breast cancer
0:47 SystImmune and BMS report dual-endpoint Phase 3 interim win for Iza-bren in TNBC
1:36 Gedeon Richter and FimmCyte partner on FMC2 antibody for endometriosis
2:04 Gedeon Richter buys Celmatix women’s health discovery portfolio
2:42 ŌURA rolls out proprietary women’s health AI model for Oura Advisor
3:15 Canada women’s health leaders push a national framework linked to Bill S-243
3:46 MediKarma acquires Nanell pregnancy journey solution from Niterra
4:14 EncorVita Health acquires menopause and sexual health education assets from Eterna
4:42 How to reach us
Transcript
Welcome to the latest edition of Women’s Health Updates, covering breakthroughs in the past two weeks. Brought to you by LucidQuest.
The FDA accepted Roche’s NDA for giredestrant, an oral SERD, in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer following prior endocrine-based therapy, including post-CDK4/6 settings. The application is supported by the Phase 3 evERA Breast Cancer study, and the agency set a PDUFA date of 18 December 2026. If approved, this combination could influence prescribing patterns and payer evaluations in the endocrine-resistant setting.
SystImmune and Bristol Myers Squibb reported that a pre-specified interim topline analysis of the Phase 3 BL-B01D1-307 trial in China met dual primary endpoints of progression-free survival and overall survival. The study compares izalontamab brengitecan, also known as Iza-bren, an EGFR by HER3 bispecific antibody-drug conjugate, against physician’s choice chemotherapy in previously treated unresectable locally advanced or metastatic triple-negative breast cancer. The companies described the improvements as statistically significant and clinically meaningful, although detailed effect sizes were not disclosed.
Gedeon Richter entered a research collaboration and option-to-license agreement with FimmCyte to advance FMC2, described as a first-in-class antibody for endometriosis. The option can be exercised before initiation of first-in-human studies. The program is positioned as a potential disease-modifying approach, underscoring continued industry investment in novel modalities for endometriosis.
Gedeon Richter also acquired Celmatix’s women’s health discovery portfolio. The assets include an oral FSH receptor agonist for fertility, a JNK inhibitor positioned as a non-hormonal immunotherapy approach for endometriosis, and AMH-targeting antibodies, both agonists and antagonists, aimed at controlling ovarian folliculogenesis. Development will be led by Richter’s women’s health R&D hub in Belgium, reinforcing a multi-asset strategy across fertility, endometriosis, and ovarian ageing.
ŌURA announced the rollout of its first proprietary large language model focused on women’s health, integrated into the Oura Advisor experience and available for testing in Oura Labs. The model is described as drawing on clinician-curated sources and user biometric signals, including sleep, activity, cycle and pregnancy data, and stress metrics. The company highlighted privacy-first infrastructure and clinically grounded guidance as differentiators.
In Canada, women’s health leaders gathered on Parliament Hill for a two-day engagement linked to Senate Public Bill S-243, which proposes establishing a national framework for women’s health. The Women’s Health Coalition of Canada announced coordinated advocacy and policy efforts focused on research, access, prevention, primary care, and innovation, signaling potential implications for funding priorities and access pathways.
MediKarma acquired Nanell, a pregnancy journey-focused digital solution, from Niterra Co., Ltd. The transaction includes intellectual property, product assets, and operations, alongside a planned 60 to 90 day knowledge transfer and operational transition. MediKarma intends to integrate Nanell into its patient profile platform to expand its women’s health and value-based care capabilities.
EncorVita Health acquired menopause and sexual health education and clinical assets from Eterna. The provider-facing platform includes intellectual property originally developed through clinical practice across multi-state women’s health clinics. The acquisition is positioned to expand menopause care capabilities within medical aesthetic clinics, supporting broader screening, initiation, and follow-up services.
Stay ahead in Women’s Health research! Like, share, and subscribe for our updates. Visit www.lqventures.com or email us at info@lqventures.com for expert healthcare consulting. See you next time!
Why It Matters
- Late-line breast cancer pipelines are converging on targeted endocrine resistance (ESR1) and ADC innovation in aggressive subtypes like TNBC, with regulatory and interim Phase 3 signals landing in the same news cycle. [1][2]
- Richter is accumulating women’s health discovery programs and partnering early in endometriosis, reinforcing a multi-asset strategy across fertility, endometriosis, and ovarian ageing. [3][4]
- Femtech is shifting from general-purpose AI toward domain-tuned women’s health models, with claims of clinician curation and privacy-first infrastructure becoming key differentiators. [5]
- Policy efforts in Canada are aligning advocacy, research, and innovation around a proposed national framework, which could affect funding priorities and access debates. [6]
- Platform consolidation continues across pregnancy and menopause enablement, with acquisitions targeting workflows, education, and longitudinal patient profiles. [7][8]
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🎬 Watch on YouTube. Subscribe and never miss a video.
🧰 See our full range of services. Discover how we can help you.
📚 View the full Women’s health archive on our research hub page.
FAQ
What decision date did Roche cite for giredestrant plus everolimus?
Roche said the FDA set a PDUFA date of 18 Dec 2026 for the NDA it accepted for giredestrant plus everolimus in ESR1-mutated, ER-positive advanced breast cancer. [1]
What is izalontamab brengitecan (Iza-bren) and what did the Phase 3 interim show?
Iza-bren is described as an EGFR×HER3 bispecific ADC. SystImmune and Bristol Myers Squibb reported an interim topline analysis in a China Phase 3 trial met dual primary endpoints (PFS and OS) versus physician’s choice chemotherapy (effect sizes not provided). [2]
What is FMC2 in the Richter–FimmCyte deal?
FMC2 is described as a first-in-class antibody being advanced for endometriosis under a research collaboration with an option-to-license that can be exercised before first-in-human study initiation (timing not stated). [3]
Which Celmatix assets did Gedeon Richter say it acquired?
Richter listed an oral FSH receptor agonist (fertility), a JNK inhibitor positioned for endometriosis, and AMH-targeting antibodies (agonists and antagonists) for ovarian folliculogenesis control. [4]
Where is ŌURA testing its new women’s health AI model?
ŌURA said the proprietary model is rolling out for testing in Oura Labs and is integrated into the Oura Advisor experience, drawing on clinician-reviewed sources and user biometrics (as described by the company). [5]
What is Bill S-243 in the Canada item?
The Women’s Health Coalition of Canada linked its Parliament Hill engagement to Senate Public Bill S-243, which proposes establishing a framework for women’s health in Canada (details beyond the release not provided). [6]
Entities / Keywords
Roche (giredestrant, oral SERD, everolimus, evERA Breast Cancer, ESR1-mutated, ER-positive, HER2-negative, post-CDK4/6)
SystImmune (Biokin, izalontamab brengitecan, Iza-bren, BL-B01D1-307, NCT06382142, EGFR×HER3 bispecific ADC, TNBC)
Bristol Myers Squibb (ADC collaboration, oncology)
Gedeon Richter (women’s health R&D hub Belgium, fertility, endometriosis, ovarian ageing)
FimmCyte (FMC2 antibody, endometriosis, option-to-license)
Celmatix (FSH receptor agonist, JNK inhibitor, AMH antibodies)
ŌURA (Oura Advisor, Oura Labs, women’s health LLM, privacy-first AI)
Women’s Health Coalition of Canada (Bill S-243, national framework, Parliament Hill)
MediKarma (Nanell, pregnancy journey, value-based care, B2B2C)
Niterra Co., Ltd. (Nanell seller, venture origin noted)
EncorVita Health (menopause education, provider training, aesthetic clinics)
Eterna, Inc. (menopause and sexual health education assets)
References
https://www.roche.com/media/releases/med-cor-2026-02-20